The FDA's Anesthetic and Analgesia Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee started a two-day meeting to seek input from patients and health care experts on the clinical value and potential risks of higher opioid doses. The agency will use the feedback to determine whether higher opioid doses should be restricted or pulled from the market.
FDA committees discuss possible restrictions for high-dose opioids
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.